Tag
A 9-year-old girl with atopic dermatitis and relapsing nephrotic syndrome achieved sustained remission of both conditions after dupilumab therapy, enabling withdrawal of steroids and tacrolimus.
Autoimmune neutropenia (AiN) in adults, though rare, is a chronic condition predominantly affecting women with autoimmune comorbidities. Treatment prioritizes observation, with therapies aimed at boosting neutrophil counts or modulating imm
This phase 3 trial shows that tarlatamab combined with durvalumab significantly improves overall and progression-free survival compared to durvalumab alone as maintenance therapy post-first-line chemoimmunotherapy in extensive-stage small-c
This study reveals that dual BAFF-APRIL blockade with telitacicept distinctly remodels pathogenic autoantibodies in antiphospholipid syndrome, showing differential effects across immunoglobulin isotypes and identifying marrow plasma-cell cl
Sacituzumab tirumotecan combined with pembrolizumab significantly improves progression-free survival in PD-L1-negative advanced nonsquamous NSCLC compared to chemotherapy plus pembrolizumab, offering a promising new treatment standard with
Immunotherapy use in older patients with advanced endometrial cancer has increased over recent years but remains lower among the oldest and racial minorities, highlighting persisting treatment disparities.
This study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precisio
This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patie
A phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.
FGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therap
This study highlights the prevalence, clinical features, and management challenges of immune-related thyroid and diabetes toxicities in gynecologic cancer patients treated with immunotherapy, emphasizing the need for proactive endocrine mon
GAD-alum immunotherapy significantly delays progression to stage 3 type 1 diabetes in children positive for the HLA-DR3-DQ2 haplotype, underscoring precision medicine’s role in managing autoimmunity.
This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with d
Recent advances in identifying leukemia-restricted antigens enable subtype-specific immunotherapies in AML that selectively target malignant cells while sparing normal hematopoiesis, offering a promising new paradigm for precision treatment
This study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.
Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.
This longitudinal study reveals that gut microbiome remodeling during immune checkpoint inhibitor therapy in advanced liver cancer patients predicts clinical benefit, improving biomarker accuracy and survival stratification.
PDS0101 combined with pembrolizumab demonstrated encouraging efficacy and safety in immune checkpoint inhibitor-naive HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, supporting further first-line evaluation.
A meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup’s treatment.
This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.
